BioSpace News Archive

Biophytis SA announced that it has filed for a pre-submission meeting request with the Food and Drug Administration to discuss filing for Emergency Use Authorization in the United States for Sarconeos in the treatment of severe forms of COVID-19.

LimmaTech Biologics AG signed an in-license agreement with GlaxoSmithKline Biologicals SA enabling LimmaTech Bio to further develop and commercialize a quadrivalent bioconjugate vaccine candidate for shigellosis that GSK added to its infectious disease pipeline when LimmaTech Bio’s predecessor company, GlycoVaxyn, was acquired by GSK in 2015.

Kernal Biologics, Inc. today announced it is presenting in person at the 3rd Annual mRNA-Based Therapeutics Summit in Boston, MA.

The Silverstein Foundation for Parkinson’s with GBA (“Silverstein Foundation”) today announced the creation of a two-year, post-doctoral fellowship program that will fund eleven scientists engaged in cutting-edge research on Parkinson’s disease in GBA mutation carriers (GBA-PD) in academic and hospital-based laboratories around the world.

Arbutus Biopharma Corporation today announced that it has scheduled its second quarter 2023 financial results and corporate update for Thursday, August 3, 2023.

Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2023.

Nusano, Inc. today announced participation in two conferences in July 2023. Nusano CEO Chris Lowe will present an overview of the company’s breakthrough radioisotope production platform at the 2nd Annual Targeted Radiopharmaceuticals Summit on July 26 in Boston.

Replimune Group, Inc. announced Sander Slootweg, founder and managing partner at Forbion, will not seek to be reappointed as a non-executive director at the end of his current term at the company’s upcoming annual general meeting.

Hillstream BioPharma, Inc. (“Hillstream”, the “Company”) today announced the expansion of its collaboration with Minotaur Therapeutics, Inc. (“Minotaur”) and its license agreement with OmniAb, Inc. (“OmniAb”) to advance the development of next generation targeted Knob biologics (PicobodiesTM) against HER3 and a new undisclosed oncology target.

New research reported at the Alzheimer’s Association International Conference® 2023 covered the breadth of Alzheimer’s disease and dementia research, including advancements in treatment, early and accurate diagnosis, and our understanding of risk factors for Alzheimer’s and other dementias.